Surasinghe S, Liatsou I, Novakova Z, Barinka C, Artemov D, Hapuarachchige S
ACS Appl Mater Interfaces. 2025; 17(8):11611-11623.
PMID: 39933703
PMC: 11873945.
DOI: 10.1021/acsami.4c16009.
Zeng T, Xie Y, Chai K, Sang H
Onco Targets Ther. 2024; 17:991-1015.
PMID: 39564453
PMC: 11573878.
DOI: 10.2147/OTT.S485869.
Wang X, Zhang X, Zhang X, Guan L, Gao X, Xu L
Eur J Nucl Med Mol Imaging. 2024; 52(3):1166-1176.
PMID: 39520516
DOI: 10.1007/s00259-024-06965-7.
Grus T, Lahnif H, Bausbacher N, Miederer M, Rosch F
Front Nucl Med. 2024; 2:892147.
PMID: 39354968
PMC: 11440839.
DOI: 10.3389/fnume.2022.892147.
Bilgin G, Bilgin C, Orscelik A, Burkett B, Thorpe M, Johnson D
Ann Nucl Med. 2024; 38(11):865-876.
PMID: 39287742
DOI: 10.1007/s12149-024-01978-6.
Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy.
Maes J, Gesquiere S, De Spiegeleer A, Maes A, Van de Wiele C
Int J Mol Sci. 2024; 25(17).
PMID: 39273701
PMC: 11396261.
DOI: 10.3390/ijms25179755.
Comparison of PSMA immunohistochemistry scoring systems to parametric [F]PSMA-1007 PET/MRI in primary prostate cancer.
Ahmadi Bidakhvidi N, Gevaert T, De Schepper M, Baldewijns M, Havinga E, Deckers W
Eur J Nucl Med Mol Imaging. 2024; 52(2):766-778.
PMID: 39269656
DOI: 10.1007/s00259-024-06903-7.
Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen.
Tayara O, Poletajew S, Malewski W, Kunikowska J, Pelka K, Kryst P
Curr Oncol. 2024; 31(8):4165-4177.
PMID: 39195294
PMC: 11352643.
DOI: 10.3390/curroncol31080311.
Prostate-Specific Membrane Antigen-Targeted Imaging and Its Correlation with HOXB13 Expression.
Angappulige D, Barashi N, Pickersgill N, Weimholt C, Luo J, Shadmani G
J Nucl Med. 2024; 65(8):1210-1216.
PMID: 38936974
PMC: 11294063.
DOI: 10.2967/jnumed.123.267301.
Effect of F-DCFPyL PET on changes in management of patients with prostate cancer: a systematic review and meta-analysis.
Wang H, Zhu H, Li G, Dai J, Huang H, Jia Q
Front Med (Lausanne). 2024; 11:1355236.
PMID: 38725467
PMC: 11079165.
DOI: 10.3389/fmed.2024.1355236.
Radioligand therapies in meningioma: Evidence and future directions.
Mair M, Tabouret E, Johnson D, Sulman E, Wen P, Preusser M
Neuro Oncol. 2024; 26(Supplement_9):S215-S228.
PMID: 38702966
PMC: 11631075.
DOI: 10.1093/neuonc/noae069.
Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?.
Tas H, Bakos G, Bauder-Wust U, Schafer M, Remde Y, Roscher M
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675472
PMC: 11053447.
DOI: 10.3390/ph17040513.
Optimizing PSMA scintigraphy for resource limited settings - a retrospective comparative study.
Kolade O, Brink A, Ayeni A, More S, Holness J
Cancer Imaging. 2024; 24(1):46.
PMID: 38556864
PMC: 10983723.
DOI: 10.1186/s40644-024-00693-9.
Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.
Zhu L, Chen P, Guo Z, Li F, Luo X, Du X
Am J Nucl Med Mol Imaging. 2024; 14(1):13-21.
PMID: 38500747
PMC: 10944373.
The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer.
Al Saffar H, Chen D, Delgado C, Ingvar J, Hofman M, Lawrentschuk N
Cancers (Basel). 2024; 16(5).
PMID: 38473301
PMC: 10931387.
DOI: 10.3390/cancers16050939.
Synthesis and Preclinical Evaluation of Two Novel Ga-Labeled Bispecific PSMA/FAP-Targeted Tracers with 2-Nal-Containing PSMA-Targeted Pharmacophore and Pyridine-Based FAP-Targeted Pharmacophore.
Verena A, Merkens H, Chen C, Chapple D, Wang L, Bendre S
Molecules. 2024; 29(4).
PMID: 38398552
PMC: 10892057.
DOI: 10.3390/molecules29040800.
Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
Maekawa S, Takata R, Obara W
Cancers (Basel). 2024; 16(3).
PMID: 38339274
PMC: 10854717.
DOI: 10.3390/cancers16030523.
Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer.
Ali I, Rezk M, Hamouda D, Talaat O, Omar Y, Abdel Tawab M
Br J Radiol. 2024; 97(1155):622-631.
PMID: 38265254
PMC: 11027301.
DOI: 10.1093/bjr/tqae021.
Current status of PSMA-targeted imaging and therapy.
Wang H, Li G, Zhao J, Eiber M, Tian R
Front Oncol. 2024; 13:1230251.
PMID: 38264741
PMC: 10803481.
DOI: 10.3389/fonc.2023.1230251.
Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [Ga]Ga-PSMA-11.
Fernandez R, Soza-Ried C, Iagaru A, Stephens A, Muller A, Schieferstein H
Cancers (Basel). 2024; 16(1).
PMID: 38201600
PMC: 10778208.
DOI: 10.3390/cancers16010173.